People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| M3 Biotechnology, Inc. | — | Biotechnology | Series C | $107.3M | $3.6B | 2018 |
Mark M. Litton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark M. Litton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Montgomery | 1 | 6 |
| Jay Wright | 1 | 2 |
| John M. Fluke, Jr. | 1 | 2 |
| John Fluke | 1 | 2 |
| Tadataka M. Yamada | 1 | 1 |
| Joseph W. Harding | 1 | 1 |
| Christina M. Thomson | 1 | 1 |
| Glenna M. Mileson | 1 | 1 |
| Hansjoerg M. Moebius | 1 | 1 |
| Michael M. Montgomery | 1 | 1 |
| Bruce Montgomery | 1 | 1 |
| Leen Kawas | 1 | 1 |
| Joseph Harding | 1 | 1 |
| Joseph M. Edelman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.